Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Joel Marrs

Concepts (169)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Aspirin
3
2015
275
1.510
Why?
Platelet Aggregation Inhibitors
3
2015
317
1.460
Why?
Diabetes Mellitus, Type 2
7
2017
1796
1.230
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
6
2020
385
1.220
Why?
Antihypertensive Agents
4
2016
443
1.210
Why?
Hypertension
5
2016
1110
1.180
Why?
Atrial Fibrillation
2
2019
331
1.100
Why?
Stroke
4
2019
820
1.040
Why?
Anticoagulants
2
2019
532
1.040
Why?
Thiophenes
2
2015
101
0.960
Why?
Allylamine
2
2012
8
0.940
Why?
Hypolipidemic Agents
3
2011
92
0.920
Why?
Internship, Nonmedical
2
2010
19
0.790
Why?
Medication Reconciliation
1
2018
30
0.760
Why?
Dyslipidemias
3
2019
154
0.680
Why?
Kidney Failure, Chronic
2
2011
420
0.670
Why?
Cardiovascular Diseases
6
2019
1585
0.650
Why?
Cholesterol, LDL
5
2019
312
0.630
Why?
Heart Failure, Diastolic
1
2015
25
0.620
Why?
Pharmaceutical Services
2
2020
89
0.620
Why?
Pharmacists
5
2020
243
0.610
Why?
Drug-Eluting Stents
1
2015
77
0.610
Why?
Ticlopidine
1
2015
67
0.600
Why?
Thromboembolism
1
2015
104
0.600
Why?
Medically Underserved Area
1
2015
84
0.590
Why?
Hypoglycemic Agents
2
2012
879
0.590
Why?
Practice Guidelines as Topic
5
2019
1525
0.570
Why?
Education, Pharmacy
3
2017
152
0.550
Why?
Patient Discharge
2
2018
624
0.540
Why?
Venous Thromboembolism
1
2015
171
0.530
Why?
Blood Pressure
3
2016
1654
0.520
Why?
Piperazines
1
2015
297
0.520
Why?
Thrombosis
1
2015
239
0.520
Why?
Guideline Adherence
1
2016
512
0.510
Why?
Urban Population
1
2015
408
0.510
Why?
Glucosides
1
2012
30
0.510
Why?
Anticholesteremic Agents
2
2012
136
0.480
Why?
Spironolactone
1
2010
36
0.460
Why?
Mineralocorticoid Receptor Antagonists
1
2010
55
0.450
Why?
Preceptorship
1
2010
58
0.420
Why?
Administration, Oral
3
2019
812
0.410
Why?
Professional Role
3
2020
170
0.400
Why?
Humans
36
2020
104249
0.390
Why?
Students, Pharmacy
1
2010
121
0.390
Why?
Medication Therapy Management
2
2020
74
0.390
Why?
Benzodiazepines
1
2008
110
0.370
Why?
Drug Therapy, Combination
4
2016
995
0.360
Why?
Hospitalization
2
2015
1486
0.350
Why?
Dipeptidyl-Peptidase IV Inhibitors
1
2007
41
0.350
Why?
Renal Dialysis
1
2010
316
0.350
Why?
Sleep Initiation and Maintenance Disorders
1
2008
112
0.350
Why?
Family Practice
2
2010
399
0.340
Why?
Hypnotics and Sedatives
1
2008
170
0.340
Why?
Insurance Coverage
1
2008
194
0.340
Why?
Certification
3
2013
95
0.340
Why?
Heart Failure
1
2018
1719
0.320
Why?
Schools, Pharmacy
2
2017
66
0.310
Why?
Faculty
2
2017
101
0.300
Why?
Poverty
1
2008
416
0.300
Why?
Ambulatory Care
1
2007
439
0.270
Why?
Specialization
3
2013
98
0.270
Why?
Aged
9
2020
18934
0.240
Why?
Colesevelam Hydrochloride
2
2012
8
0.240
Why?
Pharmacy Service, Hospital
2
2013
99
0.230
Why?
Diabetes Mellitus
2
2020
852
0.220
Why?
Brain Ischemia
2
2013
236
0.220
Why?
Secondary Prevention
3
2016
245
0.210
Why?
Cell Adhesion Molecules
1
1999
178
0.190
Why?
Blood Glucose
3
2012
1689
0.190
Why?
Age Factors
2
2016
3221
0.180
Why?
Heart Valve Diseases
1
2019
185
0.180
Why?
Middle Aged
9
2020
27633
0.180
Why?
4-Hydroxycoumarins
1
2016
7
0.180
Why?
Dissociative Disorders
1
2016
23
0.170
Why?
Vitamin K
1
2016
49
0.170
Why?
Cholesterol
3
2019
376
0.170
Why?
Community Participation
1
2017
126
0.170
Why?
Risk Factors
5
2019
8467
0.170
Why?
Female
11
2020
59707
0.170
Why?
Ischemia
1
1999
306
0.170
Why?
Clinical Trials as Topic
2
2012
979
0.170
Why?
Male
10
2020
58392
0.160
Why?
Patient Transfer
1
2018
138
0.160
Why?
Aged, 80 and over
4
2015
6518
0.160
Why?
Primary Prevention
2
2014
218
0.150
Why?
Blood Coagulation Disorders
1
2016
161
0.150
Why?
Retrospective Studies
5
2016
10064
0.150
Why?
Guidelines as Topic
1
2016
278
0.140
Why?
Suicide, Attempted
1
2016
235
0.140
Why?
Diuretics
2
2011
84
0.140
Why?
Treatment Outcome
2
2019
8608
0.140
Why?
Angiotensin-Converting Enzyme Inhibitors
2
2011
215
0.140
Why?
Societies, Pharmaceutical
2
2017
24
0.140
Why?
Acute Kidney Injury
1
1999
568
0.130
Why?
Atherosclerosis
1
2015
265
0.130
Why?
Follow-Up Studies
3
2016
4685
0.130
Why?
Acute Disease
1
2015
978
0.130
Why?
Kidney
1
1999
1121
0.120
Why?
Benzhydryl Compounds
1
2012
52
0.120
Why?
Angiotensin Receptor Antagonists
1
2011
56
0.120
Why?
Hyperlipidemias
1
2012
140
0.120
Why?
Data Collection
1
2014
674
0.120
Why?
Health Promotion
1
2017
637
0.120
Why?
Universities
1
2013
327
0.110
Why?
Sex Factors
1
2016
1913
0.110
Why?
Continuity of Patient Care
1
2013
273
0.110
Why?
Interinstitutional Relations
1
2010
69
0.110
Why?
Drug Resistance
1
2010
200
0.110
Why?
United States
6
2019
11035
0.110
Why?
Drug Monitoring
1
2010
218
0.100
Why?
Myocardial Infarction
1
2016
1062
0.100
Why?
Coronary Artery Disease
1
2015
654
0.100
Why?
Dipeptidyl Peptidase 4
1
2007
10
0.090
Why?
Patient-Centered Care
1
2013
436
0.090
Why?
Adamantane
1
2007
15
0.090
Why?
Receptors, GABA-A
1
2008
133
0.090
Why?
Pyrrolidines
1
2007
44
0.090
Why?
Adult
6
2020
30359
0.090
Why?
Exercise
1
2017
1531
0.090
Why?
Eicosapentaenoic Acid
1
2006
37
0.090
Why?
Hypertriglyceridemia
1
2006
42
0.090
Why?
Practice Patterns, Physicians'
1
2015
1117
0.090
Why?
Medication Adherence
1
2012
506
0.090
Why?
Nitriles
1
2007
114
0.090
Why?
Docosahexaenoic Acids
1
2006
61
0.090
Why?
Young Adult
4
2015
10261
0.080
Why?
Insurance, Health
1
2008
249
0.080
Why?
Aging
1
2016
1668
0.080
Why?
Fatty Acids, Omega-3
1
2006
123
0.080
Why?
Risk Assessment
2
2016
2934
0.080
Why?
Hyperglycemia
1
2009
326
0.080
Why?
Triglycerides
1
2006
540
0.070
Why?
Animals
3
2012
34264
0.070
Why?
Adolescent
4
2015
17541
0.070
Why?
Patient Compliance
1
2008
601
0.070
Why?
Enzyme Inhibitors
1
2007
944
0.070
Why?
Sleep
1
2008
647
0.060
Why?
Curriculum
1
2006
744
0.060
Why?
Integrins
1
1999
75
0.050
Why?
Annual Reports as Topic
1
2017
7
0.050
Why?
Pragmatic Clinical Trials as Topic
1
2017
36
0.050
Why?
Colorado
1
2008
4483
0.050
Why?
Organizational Policy
1
2017
84
0.040
Why?
Reperfusion Injury
1
1999
288
0.040
Why?
Advisory Committees
1
2017
196
0.040
Why?
Eating
1
2016
313
0.040
Why?
Mechanical Thrombolysis
1
2013
5
0.030
Why?
Clinical Competence
2
2011
870
0.030
Why?
Neutrophils
1
1999
1156
0.030
Why?
Thrombolytic Therapy
1
2013
105
0.030
Why?
Adrenergic Antagonists
1
2011
9
0.030
Why?
Renin
1
2011
35
0.030
Why?
Telephone
1
2013
160
0.030
Why?
Angiotensin II Type 1 Receptor Blockers
1
2011
39
0.030
Why?
Phytotherapy
1
2011
78
0.030
Why?
Calcium Channel Blockers
1
2011
172
0.030
Why?
Drug Utilization
1
2011
200
0.030
Why?
Cohort Studies
1
2020
4560
0.030
Why?
Patient Care Management
1
2010
61
0.030
Why?
Hospitals, University
1
2010
188
0.030
Why?
Governing Board
1
2009
6
0.030
Why?
Prospective Studies
1
2020
5605
0.030
Why?
Length of Stay
1
2013
984
0.020
Why?
Patient Readmission
1
2013
547
0.020
Why?
Databases, Factual
1
2013
1130
0.020
Why?
Inpatients
1
2010
265
0.020
Why?
Prevalence
1
2013
2225
0.020
Why?
Drug Combinations
1
2006
272
0.020
Why?
Primary Health Care
1
2015
1320
0.020
Why?
Marrs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2021 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)